Elazar Rabbani - Enzo Biochem Chairman
| ENZ Stock | USD 1.06 0.03 2.75% |
Chairman
Dr. Elazar Rabbani, Ph.D. is the Chairman of the Board, Chief Executive Officer, Secretary of the Company. He has authored numerous scientific publications in the field of molecular biology, in particular, nucleic acid labeling and detection. He is also the lead inventor of many of the Companys pioneering patents covering a wide range of technologies and products since 2021.
| Age | 81 |
| Tenure | 3 years |
| Professional Marks | Ph.D |
| Address | 81 Executive Blvd., Farmingdale, NY, United States, 11735 |
| Phone | 631 755 5500 |
| Web | https://www.enzo.com |
Enzo Biochem Management Efficiency
The company has Return on Asset of (0.1653) % which means that on every $100 spent on assets, it lost $0.1653. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.4501) %, meaning that it generated no profit with money invested by stockholders. Enzo Biochem's management efficiency ratios could be used to measure how well Enzo Biochem manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Enzo Biochem's Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.20 in 2024, despite the fact that Return On Capital Employed is likely to grow to (0.33). At this time, Enzo Biochem's Non Current Assets Total are fairly stable compared to the past year. Other Current Assets is likely to rise to about 2.8 M in 2024, whereas Total Assets are likely to drop slightly above 100.7 M in 2024.Similar Executives
| Found 8 records | CHAIRMAN Age | ||
| Raymond Damadian | Fonar | 81 | |
| Brian Farley | Neuronetics | 60 | |
| Erez Raphael | DarioHealth Corp | 51 | |
| Timothy MD | Fonar | 60 | |
| Yoav Shaked | DarioHealth Corp | N/A | |
| Robert Phillips | Prenetics Global | 64 | |
| Stephen Tullman | Aclaris Therapeutics | 51 | |
| JeanPaul Montupet | Prenetics Global | 66 | |
Management Performance
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.17 |
Enzo Biochem Leadership Team
Elected by the shareholders, the Enzo Biochem's board of directors comprises two types of representatives: Enzo Biochem inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Enzo. The board's role is to monitor Enzo Biochem's management team and ensure that shareholders' interests are well served. Enzo Biochem's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Enzo Biochem's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dieter MD, Chief Labs | ||
| Mary Tagliaferri, Lead Independent Director | ||
| Dov Perlysky, Lead Independent Director | ||
| Bruce Dey, Vice President - Sales and Marketing of Enzo Clinical Labs | ||
| Ian Walters, Independent Director | ||
| Matthew Kupferberg, General Secretary | ||
| David Bench, Chief Financial Officer, Senior Vice President, Treasurer, Corporate Secretary | ||
| Paul OBrien, Vice President - Global Human Resources | ||
| Gregory Bortz, Lead Independent Director | ||
| Rebecca Fischer, Independent Director | ||
| Elazar Rabbani, Chairman of the Board, Chief Executive Officer, Secretary | ||
| Bernard Kasten, Lead Independent Director | ||
| Hamid Erfanian, Chief Executive Officer, Director | ||
| Barry Weiner, President, Chief Financial Officer, Principal Accounting Officer, Treasurer, Director | ||
| Herbert Bass, Vice President - Finance | ||
| Steve Anreder, IR Contact Officer | ||
| James OBrien, Executive Vice President - Finance | ||
| Peter Clemens, Director | ||
| Bruce Hanna, Independent Director | ||
| Patricia CPA, Interim Officer | ||
| David Goldberg, VP of Corporate Devel. and General Manager of Enzo Clinical Labs | ||
| Fabian Blank, Director | ||
| Bradley Radoff, Independent Director | ||
| Dieter Schapfel, Chief Medical Director of Enzo Clinical Labs | ||
| Kara Cannon, Corporate Vice President - Commercial Operations |
Enzo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Enzo Biochem a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | 0.99 % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 2.78 M | ||||
| Shares Outstanding | 51.23 M | ||||
| Shares Owned By Insiders | 24.19 % | ||||
| Shares Owned By Institutions | 39.57 % | ||||
| Number Of Shares Shorted | 720.55 K | ||||
| Price To Earning | 26.60 X |
Pair Trading with Enzo Biochem
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enzo Biochem position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enzo Biochem will appreciate offsetting losses from the drop in the long position's value.Moving together with Enzo Stock
| 0.77 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
Moving against Enzo Stock
| 0.78 | AA | Alcoa Corp Financial Report 17th of July 2024 | PairCorr |
| 0.74 | XOM | Exxon Mobil Corp Earnings Call This Week | PairCorr |
| 0.72 | MMM | 3M Company Earnings Call This Week | PairCorr |
| 0.61 | CAT | Caterpillar Earnings Call Tomorrow | PairCorr |
| 0.59 | CVX | Chevron Corp Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Enzo Biochem could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enzo Biochem when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enzo Biochem - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enzo Biochem to buy it.
The correlation of Enzo Biochem is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enzo Biochem moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enzo Biochem moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enzo Biochem can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enzo Biochem. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Enzo Stock please use our How to Invest in Enzo Biochem guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Complementary Tools for Enzo Stock analysis
When running Enzo Biochem's price analysis, check to measure Enzo Biochem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enzo Biochem is operating at the current time. Most of Enzo Biochem's value examination focuses on studying past and present price action to predict the probability of Enzo Biochem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enzo Biochem's price. Additionally, you may evaluate how the addition of Enzo Biochem to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |
Is Enzo Biochem's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enzo Biochem. If investors know Enzo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enzo Biochem listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.47) | Revenue Per Share 0.657 | Quarterly Revenue Growth 0.138 | Return On Assets (0.17) | Return On Equity (0.45) |
The market value of Enzo Biochem is measured differently than its book value, which is the value of Enzo that is recorded on the company's balance sheet. Investors also form their own opinion of Enzo Biochem's value that differs from its market value or its book value, called intrinsic value, which is Enzo Biochem's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enzo Biochem's market value can be influenced by many factors that don't directly affect Enzo Biochem's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enzo Biochem's value and its price as these two are different measures arrived at by different means. Investors typically determine if Enzo Biochem is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enzo Biochem's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.